Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

Tarsus (NASDAQ: TARS) will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Tarsus (NASDAQ: TARS) will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026. A live webcast will begin at 1:30 p.m. PT / 4:30 p.m. ET, with a recorded replay available on the company website and archived for about 90 days.

The company will provide a corporate update during the call; investors can access the live webcast via the company’s investor site.

Argus Feb 18 session

+0.78% close to close Open Argus

Details

News Market Reaction – TARS

On Feb 18, the first trading day after this news, TARS closed 0.78% above the previous close.

Data tracked by StockTitan Argus for the Feb 18 session.

Key Figures

Earnings call time (PT): 1:30 p.m. PT Earnings call time (ET): 4:30 p.m. ET Earnings date: February 23, 2026 +1 more

Earnings call time (PT): 1:30 p.m. PT; Scheduled Q4 and full-year 2025 webcast on February 23, 2026
Earnings call time (ET): 4:30 p.m. ET; Scheduled Q4 and full-year 2025 webcast on February 23, 2026
Earnings date: February 23, 2026; Fourth quarter and full year 2025 financial results
Webcast archive duration: approximately 90 days; Recording available on company website after the call

Historical Context

5 past events · Latest: Nov 24

5 events

Nov 24
Conference participation

24h Move

-3.9%

Announced fireside chat at BTIG Ophthalmology Day with webcast details.
Nov 05
Conference participation

24h Move

-0.2%

Management participation in Guggenheim healthcare conference with webcast access.
Nov 04
Earnings release

24h Move

-4.6%

Q3 2025 results with strong XDEMVY sales growth and narrowed net loss.
Oct 28
Earnings date set

24h Move

-0.1%

Scheduled Q3 2025 earnings webcast and outlined replay availability.
Aug 27
Conference participation

24h Move

+0.6%

Planned presentations at two September 2025 investor healthcare conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/17/2026 - 04:30 PM

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Tarsus (TARS) report Q4 and full year 2025 results?

Tarsus will report on Monday, February 23, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. According to Tarsus, the company will host a live webcast that day to present fourth quarter and full year 2025 financial results and a corporate update.

How can investors access the Tarsus (TARS) earnings webcast on February 23, 2026?

Investors can join the live webcast via the company’s investor website at the scheduled time. According to Tarsus, a recorded version will be posted shortly after the call and archived on the website for approximately 90 days for later viewing.

Will Tarsus (TARS) provide a replay of the February 23, 2026 webcast?

Yes. A recorded version will be available shortly after the webcast and archived for about 90 days. According to Tarsus, the replay will be posted on the company website so investors can review the corporate update and financial commentary.

What time is the Tarsus (TARS) investor call for Q4 and full year 2025 results?

The investor call begins at 1:30 p.m. PT / 4:30 p.m. ET on February 23, 2026. According to Tarsus, the live webcast will include financial results and a corporate update and will be accessible through the company’s investor relations page.

Will Tarsus (TARS) discuss a corporate update during the February 23, 2026 webcast?

Yes. The company will provide a corporate update alongside financial results during the webcast. According to Tarsus, the presentation will cover fourth quarter and full year 2025 results plus a corporate update for investors and analysts.

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026